留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

老年药物性肝损害的临床特点

唐险峰 孙杰 路明珠

唐险峰, 孙杰, 路明珠. 老年药物性肝损害的临床特点[J]. 药学实践与服务, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
引用本文: 唐险峰, 孙杰, 路明珠. 老年药物性肝损害的临床特点[J]. 药学实践与服务, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
TANG Xian-feng, SUN Jie, LU Ming-zhu. The clinical features of drug-induced liver injury in elderly[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
Citation: TANG Xian-feng, SUN Jie, LU Ming-zhu. The clinical features of drug-induced liver injury in elderly[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006

老年药物性肝损害的临床特点

doi: 10.3969/j.issn.1006-0111.2013.01.006

The clinical features of drug-induced liver injury in elderly

  • 摘要: 药物引起的肝毒性是老年人肝脏疾病的重要原因,发生率是年轻人的4倍多,且类型几乎包括了所有已知的肝脏疾病。因为大多数的临床试验排除了大于75~80岁年龄组患者,有关药物副作用的报告在大于60岁年龄组中相当罕见。为此,需要进一步的临床研究,以探讨老年患者肝脏的药物副作用。本文主要综述了老年药物性肝损害的主要临床表现和诊断以及近年来常见药物(心血管药物和抗微生物药物)引起肝损伤的临床情况。
  • [1] 付 静,李志军.药物性肝病的发病机制及治疗新进展[J].天津医药,2009,37(4):333.
    [2] 王 文,于 红. 61例药物性肝病临床特点与转归分析[J].实用肝病学杂志,2008,11(3):191.
    [3] Chang CY, Schiano TD. Drug hepatotoxicity[J]. Aliment Pharmacol Ther, 2007,25:1135.
    [4] Hayes BD, Klein-Schwartz W, Barrueto Jr F. Polypharmacy and the geriatric patient[J]. Clin Geriatr Med, 2007,23: 371.
    [5] Onji M, Fujioka S, Takeuchi Y, et al. Clinical characteristics of drug-induced liver injury in the elderly[J]. Hepatol Res, 2009,39:546.
    [6] Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury[J]. World J Gastroenterol ,2008,14:6774.
    [7] Nathwani RA, Kaplowitz N. Drug hepatotoxicity[J]. Clin Liver Dis ,2006,10:207.
    [8] Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview[J]. Expert Opin Drug Saf, 2007,6:673.
    [9] Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen[J]. BMJ, 1982,284:1372.
    [10] 马 琳,刘 波. 85例老年药物型肝炎患者临床分析[J]. 实用肝病杂志, 2011, 14(1):45.
    [11] 王 林,张人凤,金 鸿,等.药物性肝损害90例临床分析[J]. 临床荟萃, 2011 ,26 (2):162.
    [12] 徐列明,林庆勋.正确认识中药的肝毒性[J]. 中华肝病杂志, 2007,15(7):534.
    [13] Lucena MI, Andrade RJ, Ferna'ndez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain[J]. Hepatology, 2006,44:850.
    [14] Kaplowitz N. Idiosyncratic drug hepatotoxicity[J]. Nat Rev Drug Discov,2005,4:489.
    [15] Chien RN, Yang LJ, Lin PY, et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study[J]. Hepatology, 1997,25:103.
    [16] Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases[J]. Hepatology, 1988,8:59.
    [17] Raúl J Andrade, Paul M, Tulkens J. Hepatic safety of antibiotics used in primary care[J]. J Antimicrob Chemother, 2011, 66: 1431.
    [18] Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitorset[J]. Ann Pharmacother, 1993,27:228.
    [19] Andrade RJ, Lucena MI, Ferna'ndez MC, et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity[J]. Eur J Gastroenterol Hepatol, 2002,14:887.
    [20] Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors[J]. Drug Saf ,2000,23:197.
    [21] Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial[J]. Am J Gastroenterol, 2009,104:356.
    [22] Lewis JH, Schiff ER. Methotrexate-induced chronic liver injury: guidelines for detection and prevention[J]. Am J Gastroenterol,1988,88:1337.
  • [1] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
    [2] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [3] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [4] 张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫.  基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
    [5] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [6] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
  • 加载中
计量
  • 文章访问数:  2197
  • HTML全文浏览量:  231
  • PDF下载量:  171
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-04-25
  • 修回日期:  2012-11-12

老年药物性肝损害的临床特点

doi: 10.3969/j.issn.1006-0111.2013.01.006

摘要: 药物引起的肝毒性是老年人肝脏疾病的重要原因,发生率是年轻人的4倍多,且类型几乎包括了所有已知的肝脏疾病。因为大多数的临床试验排除了大于75~80岁年龄组患者,有关药物副作用的报告在大于60岁年龄组中相当罕见。为此,需要进一步的临床研究,以探讨老年患者肝脏的药物副作用。本文主要综述了老年药物性肝损害的主要临床表现和诊断以及近年来常见药物(心血管药物和抗微生物药物)引起肝损伤的临床情况。

English Abstract

唐险峰, 孙杰, 路明珠. 老年药物性肝损害的临床特点[J]. 药学实践与服务, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
引用本文: 唐险峰, 孙杰, 路明珠. 老年药物性肝损害的临床特点[J]. 药学实践与服务, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
TANG Xian-feng, SUN Jie, LU Ming-zhu. The clinical features of drug-induced liver injury in elderly[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
Citation: TANG Xian-feng, SUN Jie, LU Ming-zhu. The clinical features of drug-induced liver injury in elderly[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 22-23,66. doi: 10.3969/j.issn.1006-0111.2013.01.006
参考文献 (22)

目录

    /

    返回文章
    返回